MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
28.44
+2.15
+8.18%
After Hours: 28.50 +0.06 +0.20% 19:57 02/06 EST
OPEN
27.51
PREV CLOSE
26.29
HIGH
28.47
LOW
26.89
VOLUME
3.69M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
18.92
MARKET CAP
3.21B
P/E (TTM)
-13.4265
1D
5D
1M
3M
1Y
5Y
1D
The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short
Seeking Alpha · 2d ago
Notable Thursday Option Activity: WFC, SITM, VKTX
NASDAQ · 2d ago
BUZZ-Novo Nordisk, obesity firms drop on report of Hims Wegovy pill copy launch
Reuters · 3d ago
Viking Therapeutics Inc. published an update to their financial calendar
Reuters · 3d ago
Viking Therapeutics Inc. kündigt Veröffentlichung neuer Finanzergebnisse an
Reuters · 3d ago
BUZZ-US-listed Novo shares slip after company flags sharp 2026 sales drop
Reuters · 5d ago
STRUCTURE THERAPEUTICS DOWN 5.3%, VIKING THERAPEUTICS DOWN 3.3%, AMGEN DOWN 1.4%
Reuters · 5d ago
OBESITY DRUGMAKERS AND DEVELOPERS FALL AFTER RIVAL NOVO NORDISK WARNS OF STEEP 2026 SALES DECLINE
Reuters · 5d ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.